Want to see AU:REG full AI Analyst Report?
Top Page
Regis Healthcare Ltd.
(Sydney:REG)
Select Model
Select Model
Rating:56Neutral
Price Target:
AU$6.50
▲(10.36% Upside)
Action:Reiterated
Date:11/28/25
Regis Healthcare Ltd. demonstrates positive technical momentum and operational efficiency, contributing to a moderate overall score. However, financial risks due to high leverage and a high P/E ratio indicating potential overvaluation are significant concerns. The lack of earnings call data and corporate events limits further insights.
Positive Factors
Revenue recovery
A return to positive revenue growth indicates the core aged‑care services are stabilizing and demand is recovering. Sustained top‑line growth supports capacity utilization, government funding capture and incremental margin upside over the medium term.
Negative Factors
High leverage / negative equity
Negative equity and elevated leverage materially constrain financial flexibility and increase refinancing risk. Over the medium term this raises cost of capital, limits strategic investment capacity, and heightens vulnerability to interest rate or funding stress.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue recovery
A return to positive revenue growth indicates the core aged‑care services are stabilizing and demand is recovering. Sustained top‑line growth supports capacity utilization, government funding capture and incremental margin upside over the medium term.
Read all positive factors
Regis Healthcare Ltd. (REG) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.97B
Dividend Yield2.3%
Average Volume (3M)1.72M
Price to Earnings (P/E)51.6
Beta (1Y)0.94
Revenue Growth14.95%
EPS Growth151.90%
CountryAU
Employees11,000
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.13
Shares Outstanding302,361,500
10 Day Avg. Volume1,078,239
30 Day Avg. Volume1,722,836
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)-141.20
Price to Sales (P/S)2.05
P/FCF Ratio10.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$7.87Price Target Upside33.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.18
Revenue Forecast (FY)AU$1.39B
Regis Healthcare Ltd. Business Overview & Revenue Model
Company Description
Regis Healthcare Limited is a leading Australian provider specializing in comprehensive care services for the elderly. The company operates a network of residential aged care facilities and delivers a broad spectrum of in-home support. These home-...
How the Company Makes Money
Regis Healthcare primarily makes money by providing residential aged care services in its facilities. Revenue is generated from (1) government funding associated with eligible residents’ care needs (typically the largest component of revenue in Au...
Regis Healthcare Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
40
Negative
Cash Flow
55
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.25B | 1.15B | 1.01B | 771.48M | 717.89M | 685.87M |
| Gross Profit | 139.90M | 141.46M | 47.17M | -3.78M | 5.18M | 67.54M |
| EBITDA | 169.58M | 240.44M | 191.45M | 96.81M | 55.86M | 82.65M |
| Net Income | 38.03M | 48.95M | -21.41M | -28.45M | -38.80M | 19.95M |
Balance Sheet | ||||||
| Total Assets | 2.60B | 2.11B | 1.81B | 1.71B | 1.76B | 1.75B |
| Cash, Cash Equivalents and Short-Term Investments | 197.97M | 192.47M | 64.91M | 61.32M | 4.15M | 3.89M |
| Total Debt | 7.99M | 5.11M | 3.84M | 71.07M | 113.32M | 153.41M |
| Total Liabilities | 2.63B | 2.12B | 1.84B | 1.67B | 1.68B | 1.61B |
| Stockholders Equity | -29.95M | -16.72M | -22.89M | 38.39M | 79.01M | 141.97M |
Cash Flow | ||||||
| Free Cash Flow | 233.44M | 219.64M | 186.57M | 53.73M | 67.60M | 87.75M |
| Operating Cash Flow | 389.26M | 306.11M | 252.30M | 105.16M | 114.79M | 105.03M |
| Investing Cash Flow | -320.67M | -132.74M | -136.59M | 6.58M | -48.62M | 7.50M |
| Financing Cash Flow | -50.54M | -45.81M | -112.12M | -43.17M | -62.39M | -119.47M |
Regis Healthcare Ltd. Technical Analysis
Positive
5.89
Price Trends
6.29
Positive
6.34
Positive
6.71
Negative
Market Momentum
0.06
Negative
56.10
Neutral
84.63
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:REG, the sentiment is Positive. The current price of 5.89 is below the 20-day moving average (MA) of 6.29, below the 50-day MA of 6.29, and below the 200-day MA of 6.71, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 56.10 is Neutral, neither overbought nor oversold. The STOCH value of 84.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:REG.
Regis Healthcare Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$9.90B | 36.53 | 5.75% | 2.25% | 8.65% | 3233.99% | |
59 Neutral | AU$414.07M | 14.93 | 16.35% | 4.60% | 1.12% | -12.02% | |
56 Neutral | AU$1.97B | 51.58 | -162.99% | 2.30% | 14.95% | 151.90% | |
55 Neutral | AU$745.71M | 53.19 | 2.05% | 2.65% | 56.28% | 55.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$51.95M | -0.41 | -131.13% | ― | 2086.71% | -116.20% |
* Healthcare Sector Average
AU:REG
Regis Healthcare Ltd.
6.51
-1.15
-14.97%
AU:RHC
Ramsay Health Care
44.12
8.21
22.85%
AU:IDX
Integral Diagnostics Ltd.
2.00
-0.47
-19.06%
AU:ACL
Australian Clinical Labs Ltd
2.25
-0.40
-14.93%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.30
-93.75%
Regis Healthcare Ltd. Corporate Events
Regis Healthcare Issues New Unquoted Performance Rights Under Staff Incentive Plan
Jun 25, 2026
Regis Healthcare Limited has issued 17,085 new performance rights under its employee incentive scheme, with these securities not intended to be quoted on the ASX. The unquoted performance rights, issued on June 25, 2026, form part of the company&#...
Regis Healthcare reports lapse of performance rights and updates capital structure
Jun 22, 2026
Regis Healthcare Limited has reported the cessation of 782,814 performance rights, which lapsed after certain conditions attached to these rights were not met or could no longer be satisfied. The lapse reduces the pool of potential future equity i...
Regis Healthcare Discloses Final Director Interest as Linda Mellors Exits Board
Jun 19, 2026
Regis Healthcare has announced that director Linda Jane Mellors ceased to be a director on 19 June 2026, triggering the lodgement of a final director’s interest notice with the ASX. The notice details Mellors’ holdings at cessation, in...
Regis Director Trims Indirect Stake to Cover Personal Tax Obligations
May 7, 2026
Regis Healthcare has disclosed a change in the shareholding of director Linda Jane Mellors, who holds an indirect interest in the company through the Davies and Mellors Family Trust. The filing outlines her role as director of the trustee company ...
Regis Healthcare appoints Andrew Kinkade as new CEO to drive growth and transformation
Apr 28, 2026
Regis Healthcare has announced the appointment of Andrew Kinkade as its new Managing Director and Chief Executive Officer, effective 20 July 2026, succeeding Dr Linda Mellors. Kinkade brings more than two decades of experience across aged care, he...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.